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Abstract
The scale-up of antiretroviral therapy (ART) in Malawi was based on a public health approach adapted to its
resource-poor setting, with principles and practices borrowed from the successful tuberculosis control framework.
From 2004 to 2015, the number of new patients started on ART increased from about 3000 to over 820,000. Despite
being a small country, Malawi has made a significant contribution to the 15 million people globally on ART and has
also contributed policy and service delivery innovations that have supported international guidelines and scale up in
other countries. The first set of global guidelines for scaling up ART released by the World Health Organization (WHO)
in 2002 focused on providing clinical guidance. In Malawi, the ART guidelines adopted from the outset a more
operational and programmatic approach with recommendations on health systems and services that were needed
to deliver HIV treatment to affected populations. Seven years after the start of national scale-up, Malawi launched a
new strategy offering all HIV-infected pregnant women lifelong ART regardless of the CD4-cell count, named Option
B+. This strategy was subsequently incorporated into a WHO programmatic guide in 2012 and WHO ART guidelines in
2013, and has since then been adopted by the majority of countries worldwide. In conclusion, the Malawi experience
of ART scale-up has become a blueprint for a public health response to HIV and has informed international efforts to
end the AIDS epidemic by 2030.
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Background
In 2004, Malawi, which is one of the poorest coun-
tries in the world [1], started scaling up antiretroviral
therapy (ART) on a national scale. Since 1985, the
country had been struggling to cope with a massive
HIV/AIDS epidemic, and when ART scale-up began
in 2004, approximately 930,000 people (approximately
10 % of the population) were thought to be HIV-
infected, there were an estimated 100,000 new HIV
infections occurring annually and 170,000 people were
thought to be in immediate need of ART without
which they were likely to be dead within 2 years [2].
In January 2004, before the national scale-up of ART
started, there were just nine facilities in the public sector
delivering ART to about 3000 patients. Treatment was
unstructured, few health care workers had received for-
mal training in ART, patients in general had to pay for
medication, and there were no national systems of moni-
toring and evaluation. Patients had restricted access to
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ART largely due to the requirement for CD4-cell count
testing for which patients had to pay out of their own
pocket. National ART guidelines, which were developed
by a working technical committee formed by the Na-
tional AIDS Commission and which were published in
late 2003, laid out for the first time a simplified and
standardised approach taking into account the severe
health system constraints and the huge epidemic burden
of disease [3]. These guidelines informed the national
scale up plan that was launched in February 2004.
Within 4 months, ART was being delivered at health
facilities within the public sector, with treatment rapidly
brought to scale in both public and private sectors in the
subsequent years. By 30th June 2015, (11 years after the
start of national scale-up) there were 711 ART clinics in
the public and private sector that had newly registered
820,367 patients on ART [4]. Both the public and private
health sectors implement the same standardised systems
of delivering and monitoring treatment, and by the end
of June 2015 a total of 565,105 patients were recorded as
alive and on ART (see Table 1). Despite the large num-
ber of patients who died soon after accessing ART or
who were lost to follow-up (which included unreported
deaths), ART was estimated to have averted 275,000
deaths in Malawi [5].
Of the 15 million people globally living with HIV/
AIDS and accessing ART as of mid-2015, over two thirds
are in Africa [6]. Despite being a small country, Malawi
has made a significant contribution to achieving this
total both in terms of contributing substantial numbers
of people on treatment and, importantly, contributing
policy and service delivery innovations that have sup-
ported scale up in other countries. The aim of this paper
is to discuss Malawi’s preparations and implementation
of ART scale up at the national level over the last 15
years and to assess how these have influenced the think-
ing and development of international guidelines.
The thinking behind Malawi’s First ART Guidelines
The Durban World AIDS Conference in 2000 was a
turning point for sub-Saharan Africa in the fight
against HIV/AIDS, and within the next 2–3 years a
number of key events took place. The UN Secretary
General Kofi Annan conceived the Global Fund to
Fight AIDS, Tuberculosis and Malaria (GFATM). Presi-
dent GW Bush of the United States launched the Presi-
dent’s Emergency Fund for AIDS Relief (PEPFAR) with
ambitious targets for HIV prevention, care and treat-
ment. JW Lee, director general of the World Health
Organization (WHO), along with the joint United Na-
tions Program on HIV/ AIDS (UNAIDS), launched the
“3 by 5” initiative—with the aim of getting 3 million
people in developing countries on ART by 2005 [7].
The funds and international support to deliver and
scale up ART to HIV-infected eligible persons in sub-
Saharan Africa were now at hand.
The will to confront the HIV/AIDS epidemic in
Malawi also found new energy and direction. In 2001,
the directors and staff from the National TB Control
Programme and the National AIDS Control Programme
in Malawi published a viewpoint paper in the Lancet
outlining their thoughts on an ART Framework for the
resource-constrained arena of sub-Saharan Africa [8].
The authors proposed and discussed the goal, strategy,
policy package and key operations that would be needed
to deliver and monitor services and which were based
on those that had been successfully used for implement-
ing the global TB strategy. This paper was used by the
leadership of the National AIDS Commission and the
Ministry of Health, Malawi, as the blueprint and the
core of the country’s submission to the GFATM in 2002.
Table 1 Characteristics and outcomes of patients ever started on
antiretroviral treatment (ART) in Malawi up to June 30th, 2015
Number (%)
Total ART clinic registrations (these include first-time
ART initiations, re-initiations after treatment interruption
and patients transferring from one site to another)
1,025,754 (100)
Registration type:
First time ART initiations
ART re-initiations after treatment interruption
ART transfers from one clinic to another
820,367
11,520
193,867
(80)
(1)
(19)
Gender at ART initiation:
Male
Female
Non-pregnant
Pregnant
369,284
656,470
536,145
120,325
(36)
(64)
(82)
(18)
Age at ART initiation:
Adults aged 15 years and above
Children 0–14 years
936,603
89,151
(91)
(9)
Reason for starting ART:
Presumed severe HIV disease
Confirmed HIV infection—WHO Stage 1 or 2
Confirmed HIV infection—WHO Stage 3
Confirmed HIV infection—WHO Stage 4
Unknown
3520
447,066
467,590
100,379
7199
(<1)
(43)
(47)
(10)
(<1)
Primary outcomes by 30 June 2015:a
Alive on ART
Lost to follow up
Stopped ART
Died
565,105
174,554
3366
77,342
(69)
(21)
(<1)
(10)
Total died:
Died month 1
Died month 2
Died month 3
Died month 4 and later
19,087
11,998
7075
39,182
(25)
(16)
(9)
(50)
ART antiretroviral therapy, WHO World Health Organization, HIV human
immunodeficiency virus
athese are primary outcomes for those who were first-time ART
initiations (N = 820367
The data are taken and modified from reference 4
Harries et al. BMC Public Health  (2016) 16:938 Page 2 of 9
The country was successful about 1 year later in obtain-
ing a large grant from the GFATM for ART scale up.
The HIV Department of the Ministry of Health, working
with various other country-based stakeholders, also used
this Lancet paper to develop the nation’s first ART
Guidelines in 2003 [3], and the first national scale up
plan in 2004.
The key was simplicity and standardisation, which
took into account the weaknesses of the health sector,
the serious shortfall in trained health care workers, espe-
cially doctors, throughout the country and the principle
of equity of access—namely that the same standards of
care would apply from north to south and from central
hospital to peripheral health centre. Details of how the
national scale up was to be done, and particularly how
the response to ART was to be monitored and evaluated,
were refined in subsequent publications from Malawi in
2004 [9, 10].
At the time of national scale up, WHO had already
published two guidelines, one in 2002 and a revised
version in 2003, emphasising a public health approach
[11, 12]. The 2003 guidelines were those mainly used by
sub-Saharan African countries to guide their initial ART
scale up plans. These were valuable for clinical guidance
about i) when to start ART, ii) what antiretroviral regi-
mens to start with, iii) when and what drugs to change
to if toxicity or failure occurred, iv) how to do clinical
and laboratory monitoring and v) what to do for specific
categories of patients such as pregnant women, children
and patients with HIV-associated tuberculosis. However,
there was no specific guidance at that time from the
WHO on operational or programmatic issues such as
the process by which patients should be enrolled and
started on ART, how to monitor medication adherence,
the registration of patients, recording or reporting sys-
tems to keep track of enrolled patients and their out-
comes and drug procurement and distribution. A HIV/
AIDS technical working group in Malawi developed the
country’s first standardised guidelines using the clinical
guidance articulated in the WHO 2003 document, and
complemented this with operational and programmatic
guidance based on contextual principles of a public
health approach, borrowing heavily from the experience
with tuberculosis (Table 2) [3, 13].
Scaling up ART in Malawi
Factors important for success
A number of factors were important to the success of
national ART scale up [14]. Malawi was not a U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR)
focus country, and financial support for ART scale-up
was from one source only—the GFATM. This allowed
the country to build and sustain a cohesive national
programme with a uniform direction for scale-up and
no competing interests.
The Malawi Ministry of Health, through the director
and staff officers of the HIV Department, took clear
leadership and assumed responsibility for national scale
up. As a consequence all implementing partners and
stakeholders agreed to work together with the Ministry
to develop and use one national standardised system to
deliver and monitor ART. Standardised systems were in-
stituted in line with the national ART Guidelines, so that
at whatever type of health facility ART was being deliv-
ered (tertiary care hospital, district or mission hospital
or health centre), the same methods of assessing patients
for eligibility for treatment, initiating first line treatment,
and registering and reporting cases and outcomes were
followed. The Ministry worked fast with stakeholders, im-
plementers and donors to develop and then implement a
2-year (2004–2005) followed by a 5-year (2006–2010)
scale up plan based on the national guidelines with clear
objectives, activities and time-lines as well as specific
details about where ART delivery sites should be situated.
An ART site accreditation process was established.
This began with an intensive training schedule with
novel training and assessment methods that took place
in early 2004 and focused particularly on paramedical
officers and nurses learning the ART guidelines and
passing a formal examination based on these guidelines.
Following classroom training, the paramedical officers
and nurses had to undertake practical attachments at
experienced ART sites in order to be certified as ART
providers. Trained staff returned to their health facilities
to brief the officers in charge, the district assembly, the
neighbouring health centres and the community about
ART. The HIV Department of the Ministry of Health
then carried out a formal accreditation of the ART facil-
ity. Once accredited, the public was informed through
announcements in the media that antiretroviral drugs
(ordered some months before in good faith that the site
would pass its assessment) were available and ART
delivery could commence.
Every quarter, the HIV Department and its partners
conducted supportive supervisory and monitoring visits to
all ART sites in the country. During these visits, they
ensured that health care workers were adhering to guide-
lines, checked and collected data for national reporting,
provided encouragement and support to staff and re-
corded drug stock levels for drug forecasting and procure-
ment planning [15]. Each quarter, facilities were awarded
a certificate of excellence if the register and treatment
cards were completed according to national guidelines
and the cohort analyses had been accurately performed.
Underperforming facilities were given warnings.
In the first few years of ART scale up, the HIV Depart-
ment developed a centrally coordinated “push system”
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for ARV supply management. Six-monthly rounds of
procurement and distribution (through UNICEF) were
based on categorizing facilities according to their esti-
mated burden of disease and by the number of new and
retained patients on ART at the end of each quarter.
Pre-packed kits with starter packs (for the first 2 weeks
of treatment) and continuation packs were allocated and
distributed based on this site-level quantification. Be-
tween 2004 and 2006, no stock-outs were encountered
nationally or at individual sites [16].
Within 6 months of establishing ART in the public
sector, the private sector was brought on board with
their agreement to follow national systems, undertake a
modified weekend ART training course with an examin-
ation of competence, and be accredited in the same way
as the public sector. Private facilities received antiretro-
viral drugs free of charge, but charged patients for the
drugs at approximately USD$3.5 per course of treatment
per month. These monies were partly used to cover
dispensing costs and partly to cover other costs of the
programme, such as training and supervision.
Challenges
Challenges in the early years of ART scale up abounded.
On the technical side, few children were accessing ART
due to the absence of paediatric drug formulations and a
dearth of paediatric specialists in the country who felt
confident enough to provide care and treatment for this
sub-group of patients. There were difficulties in man-
aging patients with HIV-associated tuberculosis due to
the well- known interactions between rifampicin and
nevirapine. High early death rates after starting ART
were a concern for health care workers, patients and the
wider community-at large.
On the logistic side, huge efforts were required to keep
up with the demands for stationary (patient registers and
treatment cards), to undertake quarterly and countrywide
supervision especially during the rainy season and to en-
sure a high quality delivery of services. In more recent
times, the huge expansion of ART clinics, substantial an-
nual increases in people initiating ART and a diversifica-
tion of antiretroviral therapy regimens has put a strain on
the procurement and distribution system for antiretroviral
therapy drugs. Nevertheless, maintaining uninterrupted
drugs supplies is a top priority for the ART programme.
The April to June 2015 HIV report indicated that less than
2 % of ART sites experienced stock-outs for that quarter,
with these stock-out events typically affecting small
peripheral sites and usually being of short duration as a re-
sult of the bi-monthly scheduled distribution cycle and
the ad-hoc stock relocation facility coordinated through a
toll-free supply hotline [4].
Table 2 Main similarities and differences between the WHO 2003 ART Guidelines and the Malawi 2003 ART Guidelines
WHO 2003 ART Guidelines Malawi 2003 ART Guidelines
When to start ART Stage 4, Stage 3, Stage 2 with CD4 count or
Total Lymphocyte count below threshold,
Stage 1 with CD4 count below threshold
Followed WHO Guidance
What to start Choice of 4 first-line ART regimens based
on d4T/AZT, 3TC or EFV/NVP
One first-line ART regimen only (d4T + 3TC + NVP)
with alternatives if toxicity occurred
How to start ART No specific advice Advice about staging patients, group counselling and
individual counselling and how to manage the first
2 weeks on half-dose nevirapine
Clinical and laboratory monitoring Recommended tiered laboratory capabilities
based on level of health care facility
Emphasised clinical monitoring only due to poor
country-wide laboratory infrastructure
Adherence to medication General advice about adherence and monitoring Specific advice around pill counting
Children Advice about dosing—recommendations for not
splitting fixed-dose tablets
Advice about splitting first-line fixed-dose ART
according to weight
HIV-Tuberculosis Advice based on CD4 count or consideration of
ART based on clinical judgement
Advice about starting all HIV-infected TB patients
on ART in continuation phase with isoniazid
and ethambutol
Standardised treatment outcomes
on life-long ART
No advice given Standardised treatment outcomes defined
Programmatic monitoring,
recording and reporting
No advice given Advice about patient identity cards, patient
treatment master cards, patient ART registers and
patient cohort analysis
Supervision No advice given Advice about quarterly supervision of all ART clinics
including drug security checks
ARV drug procurement
and distribution
No advice given Advice about “start packs” and “continuation packs”
and how to forecast drug needs
ART antiretroviral therapy, WHO World Health Organization, HIV human immunodeficiency virus, TB tuberculosis, d4T stavudine, AZT zidovudine, NVP nevirapine,
EFV efavirenz
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During those early years, all countries in sub-Saharan
Africa were tasked with the challenge to rapidly scale up
ART in a context of limited resources. In order to share
experiences with its neighbours, the HIV Department
and its implementing partners presented on progress
with national scale-up along with successes and chal-
lenges at international conferences, at meetings and
committees convened by the WHO and in peer-
reviewed publications [17, 18]. Data collected from the
routine monitoring systems were used to show how
ART scale up was benefiting the health sector in terms
of reducing morbidity and mortality in health care
workers and to support the quarterly supervision to all
ART sites to ensure good quality data [19, 20]. A demo-
graphic surveillance survey in northern Malawi showed
a significant reduction in mortality amongst adults
within a year of offering ART services [21], and similar
findings were observed through a more operational
research study in the southern part of the country [22].
Using operational research to learn while doing
As there was no programmatic guidance from the WHO
during these first few years of ART scale-up, Malawi
undertook a number of operational research studies to
generate local evidence to support activities and inter-
ventions around some key areas [23].
Cotrimoxazole preventive therapy
The high early mortality being documented for patients
starting ART was of national and international concern
[24]. While the efficacy of cotrimoxazole preventive
therapy in reducing early mortality had been demon-
strated in randomized trials [25], the routine use of this
adjunctive treatment in the field was limited. An oper-
ational study implemented at ART clinics around the
country showed that cotrimoxazole preventive therapy,
given before or with ART, significantly reduced this early
mortality [26]. The presentation of these data, along with
additional evidence from other studies in Africa, led to a
national policy decision that cotrimoxazole preventive
therapy should always be given and continued indefin-
itely in any person starting ART: this policy was included
in the second edition of the Malawi ART Guidelines
[27], and formed part of the evidence base for the WHO
2006 guidelines on cotrimoxazole prophylaxis [28].
Task shifting and decentralisation
As ART scale up progressed, the need for increased ex-
pansion of services to rural areas became a priority
among stakeholders. After much discussion, the medical
and nursing councils of Malawi (who have regulatory re-
sponsibility and lay down the terms of reference for
what doctors, paramedical officers and nurses can and
cannot do) authorized nurses to initiate ART and the
decision was made to extend HIV treatment services to
peripheral health centres. This policy of task shifting and
decentralisation was reflected in the third edition of the
Malawi ART Guidelines in 2008 [29]. Subsequent oper-
ational research at health centres where nurses initiated
ART showed that this policy was feasible and effective
with treatment outcomes as good as those achieved from
district hospitals [30, 31]. This evidence, which came
several years ahead of formal evidence from randomized
trials [32], helped to inform early WHO guidance on
task shifting [33]. Subsequent experience in Malawi
piloting less frequent clinic visits for stable patients on
ART to reduce the clinic workload also informed the
2016 revision of the WHO ART guidelines [34].
Electronic medical record systems
While the national monitoring and reporting system ini-
tially performed well at facility and national level, it was
essentially paper-based, and in busy clinics the rapidly
growing cumulative burden of patients registered for
ART threatened to overwhelm the capacity to collect,
collate and analyse data on a quarterly basis. For busy
sites with over several thousand patients cumulatively
registered for ART, the tasks to manually count charac-
teristics and outcomes for each individual patient took
several days to perform each quarter and began to
detract from patient care. The need for an electronic
medical record system for use in busy clinics became an
urgent imperative.
In 2005 a task force created by the HIV Department
investigated the feasibility of introducing computers to
capture patient data and produce cohort reports at ART
clinics. Two electronic medical record system models
were considered. The first model employed a dedicated
clerk to enter patient information retrospectively from
patient treatment cards to a single desktop computer.
The second comprised computers in every clinic room,
connected to a central server that stored the data. With
the second model, designed by a local non-governmental
organization called Baobab Health Trust, healthcare
workers used simple, robust, touchscreen computers to
enter patient information during clinical encounters at
the point of care. Based on experiences of using these
touchscreen systems in various domains in healthcare in
Malawi since 2001, the task force chose the second
model and established core functionality requirements
for the touchscreen point of care system [35].
The system was first piloted at a busy ART clinic in a
central hospital in 2005 and then rolled out to further
hospital ART clinics in 2006 and 2007. Key challenges
that needed to be overcome included: i) low computer
literacy among target users, ii) the need for unique
patient identifiers, iii) maintaining clean and reliable
electrical power and iv) managing the transition from
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paper to electronic-based records and accurately back-
entering large numbers of paper-based treatment cards
and registers. Baobab Health Trust approached and
solved each of these challenges using hardware and soft-
ware innovations [35].
On-going challenges include validating the accuracy of
data in the electronic medical record system, the quar-
terly production of complete and accurate cohort re-
ports, the logistics of nationwide supervision and the
immediate attention needed when the computer-based
systems become dysfunctional at a clinic. Despite these
challenges, the system has been gradually scaled up and
by 30th June 2015, a total of 495,974 patients had ever
been registered for ART through electronic medical re-
cords at 60 government clinics throughout the country.
Malawi and Option B+
In 2010, guidance was issued from the WHO on
prevention-of-mother-to-child-transmission of HIV
(PMTCT) [36]. It was recommended that HIV-infected
pregnant women have their CD4 cell count assessed.
Women with a CD4 cell count < 350 cells/mm3 or who
were clinically immune suppressed based on WHO clin-
ical staging were to start life-long ART for their own
health while asymptomatic women with a CD4 count
≥350 cells/mm3 were to be offered Option A (maternal
zidovudine + infant antiretroviral therapy prophylaxis) or
Option B (maternal triple antiretroviral therapy prophy-
laxis). This PMTCT strategy depended on countries
having capacity to carry out CD4 testing for all HIV-
infected pregnant women.
Malawi was requested to conduct a feasibility appraisal
of this new guidance. The weak laboratory infrastructure
in the country meant that CD4 count capacity was se-
verely limited: for example, in quarter 4, 2010, only 60
out of 417 ART clinics in the country had a CD4
machine of which only 53 produced any results in that
3-month period [37]. Furthermore, antenatal care as the
main point of diagnosis and management for HIV-
infected pregnant women was highly decentralized and
over 50 % of women needing PMTCT were seen at per-
ipheral health centres. Option B (with triple ART taken
from 14 weeks gestation to 1 week after all exposure to
breast milk had ended) was the logical choice to keep
procurement and distribution streamlined and drug
administration manageable for peripheral health care
staff. However, total fertility rate in Malawi was high at
5.6 births per women with a median duration of breast-
feeding for each woman of 23 months [38]. Soon after
the breastfeeding period had finished ART would be
stopped, but many women would soon become preg-
nant again needing to restart ART. This stop-start ap-
proach to ART did not make sense programmatically.
Nor did it make sense clinically as there was also
evidence that CD4+ count guided interruption of ART
was associated with increased morbidity and an in-
creased risk of death [39].
The country therefore proposed a new strategy to offer
all HIV-infected pregnant women lifelong ART regard-
less of WHO clinical stage or CD4 cell count, named
Option B+ [38]. The rationale, the implementation and
benefits of such a strategy have been evaluated in several
studies and are shown in Table 3 [40–42]. This proposal
was translated to national policy and implemented in
Malawi in July 2011 [43]. The optimal delivery models
for Option B+ in different settings are the subject of
ongoing operational research to ensure high uptake and
retention in care [44, 45].
Despite limited evidence of efficacy, the WHO incor-
porated Option B+ into its 2012 programmatic update
on treating pregnant women and preventing HIV infec-
tion in infants [46], and then into its 2013 consolidated
ART guidelines [47]. For programmatic and operational
reasons, especially in generalized epidemics, a condi-
tional recommendation with low quality evidence was
made that all pregnant and breastfeeding women with
Table 3 Advantages of Option B+ in Malawi
Advantage Explanation
Simple to implement One tablet a day of TDF + 3TC + EFV
for the woman with NVP infant
prophylaxis for 6 weeks. Reinforces the
nationwide message that ART is taken
for life; procurement and distribution
needs for the country made easier
compared with having Option A or
Option B.
Reduced vertical transmission
from mother to child
For current pregnancy ART offers
protection from time of administration
and is continued in breast feeding
period. For future pregnancies, ART
offers protection from time of
conception.
Avoids stop-start ART Interrupted ART has risks for increased
morbidity and mortality.
Improved maternal health
and survival
Post-partum women in Zimbabwe
with CD4 count > 350 cells/mm3 have
an elevated risk of death six times
higher than non-infected women [40].
Reduced sexual transmission
of HIV to discordant couples
HIV-infected persons on ART have
significantly reduced risk of HIV
transmission through sexual
intercourse to non-infected partners
even at high CD4 cell counts [41].
Reduced risk of tuberculosis ART reduces the risk of tuberculosis in
people living with HIV, even at high
CD4 cell counts [42].
Treats hepatitis B infection Tenofovir and lamivudine are active
against hepatitis B virus, and about
15 % of people living with HIV in
Malawi are also infected with hepatitis B.
ART antiretroviral therapy, HIV human immunodeficiency virus, TB tuberculosis,
TDF tenofovir, 3TC lamivudine, EFV efavirenz, NVP nevirapine
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HIV should initiate ART as lifelong treatment. The pol-
icy, probably because of its simplicity and potential for
rapid scale up, was taken up quickly by countries, with
the majority of countries adopting PMTCT Option B+
within 2 years [48]. Subsequent WHO guidelines re-
leased in late 2015 [49] and the new guidance in 2016
[34] recommend Option B+ as the preferred way to pre-
vent mother-to-child transmission, to supersede all pre-
vious options. A recent evaluation of the first 3 years of
Option B+ in Malawi has found that the risk of loss to
follow-up during the third year is low and similar for
patients retained for 2 years, with retention remaining
stable as the Option B+ programme has matured [50].
Conclusion
The role of national policy initiatives as the driver for
international policy development can rarely be estab-
lished with certainty. Malawi’s practical and pragmatic
approach to developing national ART guidelines that ac-
knowledged health system weaknesses and services
needed to deliver and monitor treatment was well re-
ceived by the international community. The national
quarterly reports on all patients in the country being
registered for ART along with censured standardised
quarterly outcomes were unique in the early phases of
scale up [18]. Malawi’s public health stance to ART
scale-up was adapted to its resource-poor setting, and
despite pressure from both within and outside Malawi to
use advanced laboratory technology to support the initi-
ation and continuation of ART, this was resisted in
favour of a more clinical and programmatic outcome
orientated approach. This allowed a rapid and successful
countrywide scale up, opened up the possibilities of
decentralization and task shifting and paved the way for
Option B+ 7 years after the first steps in ART delivery
were taken.
Table 4 illustrates this evolution of national and inter-
national guidance along with the supporting evidence,
further demonstrating that Malawi implemented inter-
ventions based on local evidence and context often long
before there was supporting data from randomized tri-
als and before WHO had released its international
guidance [28, 32, 33, 46, 47, 51–54].
The launch of the new WHO Guidelines in 2015
recommending that ART be initiated in everyone living
with HIV at any CD4 count and that daily oral pre-
exposure prophylaxis be offered to anyone at substantial
risk of HIV infection as part of combination prevention
approaches will significantly impact global public health
[49]. These recommendations form part of the revised
consolidated guidelines on the use of ARV drugs to treat
and prevent HIV infection published by WHO in 2016
[34], and these will facilitate the achievement of
UNAIDS Fast-Track targets for 2020 [55].
Malawi had already formulated a “test and treat” ap-
proach in its’ new national strategic plan, with implemen-
tation planned for 2016. It will be a major undertaking
and one for which core principles such as uninterrupted
drug supplies, patient adherence to therapy and compli-
ance with follow-up will be needed for success, not only
in Malawi but globally as well.
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